Ocrevus
(Ocrelizumab)ApprovedMonoclonal antibody
RocheOcrelizumab is used to treat multiple sclerosis, a disease where the immune system attacks the brain and spinal cord, causing weakness and disability. It works by reducing certain immune cells that damage the nervous system.[2] Ocrevus is currently approved and in use across 8 indications[4].[1]
Ocrevus is one of 134 monoclonal antibody programs targeting Chronic Progressive Multiple Sclerosis. It is currently in Approved.
8
Indications
87
Total Trials
34
Active Trials
133
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
138 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Ocrevus
RocheApproved
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Vumerity
BiogenPhase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis39 trials
Show 36 more trials
Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Approved·NCT05285891·123 enrolled
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Active, not recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT05999604·244 enrolled
Rheumatoid Arthritis8 trials
Show 5 more trials
Primary Progressive Multiple Sclerosis6 trials
Relapsing-Remitting Multiple Sclerosis5 trials
Show 2 more trials
Relapsing Multiple Sclerosis3 trials
21 more indications
ESS2 trials
Systemic Lupus Erythematosus2 trials
Infants1 trial
Autologous Hematopoietic Stem Cell Transplantation1 trial
Effectiveness1 trial
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB
Active, not recruiting·—·Phase 3·NCT05210621·72 enrolled
Pregnancy1 trial
Immune1 trial
Progressive Multiple Sclerosis1 trial
Relapsing Remitting Multiple Sclerosis (RRMS)1 trial
Multiple Sclerosis, Relapsing-Remitting1 trial
Progressive Multiple Sclerosis (PMS)1 trial
Regulatory
FDA Approval Timeline[5]
Mar 28, 2017
OCREVUS
BLA BLA761053
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ocrevus drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ocrelizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]